Coverage
-
May 14, 2020
Biogen Inc. has secured a settlement blocking what it called a New York bioscience company's "brazen" effort to sell copycat versions of its potential blockbuster Alzheimer's drug, according to a Wednesday filing in Massachusetts federal court.
1 other articles on this case.
View all »